Company Overview of Ceregene, Inc.
Ceregene, Inc. develops adeno-associated virus (AAV) gene therapies for the treatment of neurodegenerative disorders using the delivery of nervous system growth factors. Its therapeutic programs include CERE-110, an AAV vector delivery system that is in a Phase II clinical trial for the treatment of Alzheimer’s disease. The company was incorporated in 2000 and is based in San Diego, California. As of October 1, 2013, Ceregene, Inc. operates as a subsidiary of Sangamo Biosciences Inc.
9381 Judicial Drive
San Diego, CA 92121
Founded in 2000
Key Executives for Ceregene, Inc.
Ceregene, Inc. does not have any Key Executives recorded.
Ceregene, Inc. Key Developments
Similar Private Companies By Industry
|Paradise Genomics, Inc.||United States|
|KeraCure, Inc.||United States|
|Rani Therapeutics, LLC||United States|
|Synthecon, Inc.||United States|
|Genextropy, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Ceregene, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.